This is a snippet of the transcript.Contact Salesto get full access.
Yes, every state and institution is a little different. Typically, when physicians need to earn CME, they attend conferences, which requires taking time off. Some enjoy doing that, taking their families on vacation and offsetting it. But most busy physicians don't have time. With each topic search, when they have a clinical question within UpToDate, they type in the question, review the content, and apply it. That's what gave us the credentialing capability with each topic search. So the app now allows access to UpToDate from anywhere and provides data on who's using the product. Instead of being IP authenticated and anyone utilizing it without us knowing, by integrating it within the EMR, we connect unique identifiers to know who's doing what. With anything, I think 85% of data comes from healthcare. We're gaining that data, and nowadays, UpToDate was essentially your AI before AI reached its current state.
This is a snippet of the transcript.Contact Salesto get full access.
Yes, that's a great question and one we got asked all the time. UpToDate was the most expensive; it was the Cadillac. I say Cadillac in terms of it being a great car. It was a trusted resource. It was 100% subscriber-funded. The data we provided wasn't influenced by any medical device or pharmaceutical company.
This is a snippet of the transcript.Contact Salesto get full access.
Yes, correct. It was 100% subscriber-funded and written through an editorial process by physicians aiming to educate other physicians. Regarding pricing, we increased it by over 300%. I was brought on to have those discussions because we shifted from an inpatient-outpatient pricing model to a price-per-head model. Any and everyone at the hospital could use the platform, but we only charged for clinicians within our 21 covered specialties at the time. I think we may be up to 23 or 24 now. So for example, orthopedic physicians could use UpToDate, but we didn't charge orthopedics, if that makes sense?
This is a snippet of the transcript.Contact Salesto get full access.
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2025 IP 1 Ltd. All rights reserved.